2019
DOI: 10.1001/jamanetworkopen.2018.7498
|View full text |Cite
|
Sign up to set email alerts
|

Noncommercial US Funders’ Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability

Abstract: Key Points Question What are the current policies for clinical trial registration, summary results sharing, and individual patient data sharing among the top 10 noncommercial US health research funders? Findings In this review study, 6 of 9 (67%) of the top US funders have a publicly available written policy addressing all 3 major trial transparency domains. However, fewer US funders require specific transparency actions in these domains (11%-56%) or monito… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
20
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 14 publications
(23 citation statements)
references
References 14 publications
2
20
0
Order By: Relevance
“…Two studies using similar methods evaluated trial transparency policies (i.e., those related to trial registration, access to summary results, individual data availability) for non-commercial health research funders globally (n=18) 34 and in the USA (n=9) 36 . After accounting for three common funders across studies, 21 of 24 (87.5%) funders (16 of which are represented in our study) either required or supported publication or registration of trial results (neither study or their available data distinguished between publication or registration).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Two studies using similar methods evaluated trial transparency policies (i.e., those related to trial registration, access to summary results, individual data availability) for non-commercial health research funders globally (n=18) 34 and in the USA (n=9) 36 . After accounting for three common funders across studies, 21 of 24 (87.5%) funders (16 of which are represented in our study) either required or supported publication or registration of trial results (neither study or their available data distinguished between publication or registration).…”
Section: Discussionmentioning
confidence: 99%
“…While there are some inequities in its coverage (e.g. public funders were selected from only G20 countries; paucity of funders from low income countries), the list is likely the most comprehensive source of global health research funder expenditure information in existence (personal communication, Dr. Beverley Holmes, CEO, Michael Smith Foundation for Health Research) and has been used to construct samples in at least two other studies 34 , 36 . This study excludes commercial funders since their expenditure data are not publicly or readily available.…”
Section: Methodsmentioning
confidence: 99%
“…Two studies using similar methods evaluated trial transparency policies (i.e., those related to trial registration, access to summary results, individual data availability) for non-commercial health research funders globally (n=18) 32 and in the USA (n=9) 34 . After accounting for three common funders across studies, 21 of 24 (87.5%) funders (16 of which are represented in our study) either required or supported publication or registration of trial results (neither study or their available data distinguished between publication or registration).…”
Section: Discussionmentioning
confidence: 99%
“…While there are some inequities in its coverage (e.g. public funders were selected from only G20 countries; paucity of funders from low income countries), the list is likely the most comprehensive source of global health research funder expenditure information in existence (personal communication, Dr. Beverley Holmes, Michael Smith Foundation for Health Research) and has been used to construct samples in at least two other studies 32,34 . This study excludes commercial funders since their expenditure data are not publicly or readily available.…”
Section: Data Sourcementioning
confidence: 99%
“…Prompted by these and related activities, the biomedical research community around the world has begun considering best practices to ensure value in publicly-funded research. As key contributors 7 , research funders are encouraged to audit and update their own policies and practice, even as external assessments of funders are also undertaken 8, 9 .…”
Section: Introductionmentioning
confidence: 99%